The tweet was deleted by the author.
But we saved everything 🙂.
Verastem, Inc. is intensifying efforts to incorporate patient stories into research and understanding of ovarian cancer, with a particular emphasis on the rare low-grade serous ovarian cancer subtype.
In the latest episode of the NOCC National Teal Talk Podcast, Emily Campbell, executive director and co-founder, addressed the importance of first-hand patient experiences. The company aims to promote greater awareness and accelerate research by elevating the voices of those affected by this rare form of cancer. Details regarding further initiatives and outcomes are expected as these patient-led collaborations progress.
Verastem, Inc. recently launched an awareness campaign targeting KRAS-mutated low-grade serous ovarian cancer to highlight available FDA-approved treatments. The company also scheduled its first quarter earnings call for May 7 at 4:30pm ET to deliver financial results and corporate updates. These initiatives follow continued efforts to engage and inform both patients and stakeholders.